Metraipolis › archive › dc_100644dba603

Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42137821
DOI
10.1093/noajnl/vdag013
License (as archived)
solo-consultazione
Archived
2026-11-06T13:08:05.084Z
SHA-256 of the archived text
457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777
Stable URL of this page
https://metraipolis.com/documento/dc_100644dba603

How to cite

Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821 — Europe PMC (en), https://europepmc.org/article/MED/42137821 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_100644dba603 (Metraipolis archive dc_100644dba603, sha256 457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777)
BibTeX
@misc{dc100644dba603,
  title = {Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis — Europe PMC PMID:42137821},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42137821},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_100644dba603; sha256 457e8e21170345bfd654a0e99f74b449f675e49af72206a469a23cfbdff43777},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42137821. Agents can read the archived copy with the MCP tool read_document.